These novel treatments, Tirzepatide , represent a significant advancement in managing metabolic dysfunction and conceivably other disorders. They are grouped as GLP-1 receptor agonists , indicating they to replicate the endogenous GLP-1 peptide, boosting insulin release and lowering food intake.